Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

Inclusion Criteria

• •1. Has histologically confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded).
• •2. Have progressed from at least 2 lines of standard treatment,including fluoropyrimidines, irinotecan, oxaliplatin, with or without targeted drugs, like bevacizumab and cetuximab (only for RAS wild-type). Regorafenib was permitted but not required for inclusion.
• •3. Has measurable or non-measurable disease as defined by RECIST version 1.1
• •4. Is able to swallow oral tablets.
• •5. Estimated life expectancy ≥12 weeks.
• •6. Eastern Cooperative Oncology Group performance status (ECOG PS) less than 2
• •7. Has adequate organ function.